ADAM17 and Sepsis: Genetic attenuation of ADAM17 in myeloid cells or hepatocytes reduces circulating TNF-α levels and improves survival following LPS challenge [38,39], while small-molecule ADAM17 inhibitors have demonstrated anti-inflammatory effects in sepsis models [27].